In the SUBER study, a group of people with drug-resistant epilepsy will be implanted with a novel minimally-invasive subcutaneous (“under-the-skin”) EEG device, which will be used to monitor brain activity for up to 15 months, together with a non-invasive wrist-worn sensor and an electronic diary.
We aim (1) to investigate whether features derived from continuously-recorded ultra-longterm subcutaneous EEG can forecast future seizure occurrences in people with epilepsy; and (2) to substantially improve understanding of the factors associated with seizure occurrence, such as stress, poor sleep, and naturally-occurring seizure cycles.
Our vision is that a better understanding of seizure predictability and risk factors for seizure occurrence will allow the development of new strategies to reduce seizures, save lives, and save healthcare costs.
Funded by the Epilepsy Foundation of America’s My Seizure Gauge Program
ClinicalTrials.gov Identifier: NCT04061707
Sponsor: King’s College London